Clinical Trials
6 trialsNCT03367741 2026-06-02
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03660826 2026-06-02
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT04513665 2025-05-22
ZW25 in Women With Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03241745 2024-12-27
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated